Our experiments targeting the production of GluCer by inhibiting the rate‐limiting UGCG enzyme are promising, as a significant reduction in cell proliferation was observed upon UGCGi treatment, namely using the well‐tolerated eliglustat approved for Gaucher disease type 1.54, 55. The gene discussed is UGCG; the disease is Gaucher disease type 1.